1 March 2008 in The Annals of Thoracic Surgery
The treatment strategy of acute intramural hematoma involving the ascending aorta remains uncertain. The objective of this study was to evaluate the effectiveness of surgical treatment for this condition. A total of 41 patients underwent operation for acute intramural hematoma involving the ascending aorta between 2000 and 2006. Mean age was 67.2 +/- 10.1 years, with 26 female patients and 10 in cardiogenic shock at presentation. Early and midterm results, including mortality, morbidity, survival, event-free rates, and the persistence of residual hematoma, were analyzed retrospectively in all patients. Mean follow-up period was 29.7 +/- 18.1 months. All but one patient underwent operation within 72 hours from the onset of symptoms. Thirty-four patients underwent isolated ascending aortic replacement, three had hemiarch repair, and four required total arch replacement. There were no in-hospital deaths. Stroke occurred in two patients and transient neurologic dysfunction in one. Postoperative computed tomographic scan showed residual distal hematoma progression to classical double-barrel dissection in two patients. At five years follow-up, survival was 100%. During the follow-up period, one patient had a new type B aortic dissection. A follow-up study confirmed hematoma resorption in 29 patients (70.7%). The estimated freedom from intramural hematoma-related events was 92.6 +/- 4.1% at five years. No independent predictor of intramural hematoma-related events was found on multivariate analysis. Immediate surgical treatment of acute aortic intramural hematoma involving the ascending aorta with open distal replacement of ascending aorta results in lower mortality rates and excellent midterm survival.
18 February 2025 in The Heart Surgery Forum
Background: Although sutureless aortic valve replacement is rising in popularity, there are few reports on its use in patients on dialysis. This study aimed to investigate the early and mid-term surgical outcomes of the procedure in these patients. Methods: Twenty-one dialysis (mean age, 77.4 ± 5.2 years) patients with aortic stenosis who underwent aortic valve replacement with sutureless and rapid deployment prostheses between May 2019 and March 2021 were enrolled. We retrospectively reviewed and analyzed the clinical courses of all dialysis patients. Data on patient characteristics, surgical procedures, and postoperative outcomes (survival times and major adverse cardiac and cerebrovascular events) were collected. The mean follow-up duration was 371 days (interquartile range (IQR) 364–399). Results: Two (9.5%) operative deaths occurred within 30 days of surgery. The 1-year survival was 85.7%, and the rates of freedom from cardiac death, myocardial infarction, and stroke were 95.0%, 89.7%, and 95.0%, respectively. 1 year freedom from major adverse cardiac and cerebrovascular events was 67.8%. There was one (5.5%) permanent pacemaker implantation 9 months after surgery. No reoperations were performed for any cause. Three patients had moderate prosthesis-patient mismatch 4–7 days after surgery. Effective orifice area index improved from 0.74 cm2/m2 to 0.87 cm2/m2 in one patient 1 year after surgery. No cases of structural valve deterioration or a paravalvular leak were observed. Conclusions: Sutureless aortic valve replacement in dialysis patients may be a novel treatment strategy with lower early mortality rates comparable to those of conventional treatments, increased freedom from pacemaker implantation, and good valve function.
17 April 2025 in The Heart Surgery Forum
Background: Sutureless valves are gaining interest for aortic valve replacement in patients with small annuli; however, their effectiveness compared to traditional valves remains unclear. This study aimed to explore the clinical outcomes and hemodynamic performance of sutureless versus stented valves. Methods: In total, 190 patients underwent aortic valve replacement (AVR) at two hospitals from May 2019 to March 2022; 60 patients underwent AVR with Perceval S sutureless aortic valves S size (P group), and 130 underwent AVR with INSPIRIS RESILIA 19 mm (I-19 group) or 21 mm valves (I-21 group). We retrospectively reviewed and analyzed the patient characteristics and intra- and postoperative outcomes. Results: The mean cardiopulmonary bypass (CPB) and aortic cross-clamp (ACC) times were significantly shorter in the P group than in the I group. There were no significant differences in intensive care unit length of stay, hospitalization, and 30-day mortality. The echocardiographic evaluation showed no significant differences in prosthesis performances between the P group and I-19 group 4–7 days after surgery. However, the performance in the I-21 group significantly differed from that in the P group. At the 1 year follow-up, prosthesis performance in the P group was equivalent to that in the I-21 group. Conclusions: Surgical intervention with S size Perceval S sutureless valves is a safe and effective treatment for patients with a small aortic annulus and demonstrates superior intermediate-term hemodynamic performance.